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Abstract
Hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease that necessitates 
liver transplantation. The incidence of virus-induced cirrhosis and hepatocellular carcinoma 
continues to increase, making liver transplantation increasingly common1–3. Infection of the 
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engrafted liver is universal and increases progression to advanced liver disease, with 20–30% 
displaying cirrhosis within 5 years. While treatments of chronic HCV infection have improved 
dramatically, albeit with remaining challenges of failure and access, therapeutic options to prevent 
graft infection during liver transplantation are emerging. Recent developments in directed use of 
novel direct-acting antiviral (DAA) agents4–6 to eliminate circulating HCV prior or following 
transplantation bring renewed hope for prevention and treatment of liver graft infection. 
Identifying the ideal regimen and use of DAAs reveals new paradigms of treatment for this special 
population6–8. Complementing DAAs, entry inhibitors have been shown to prevent liver graft 
infection in animal models9–13 and delay graft infection in clinical trials14, providing a perspective 
to be used concomitant to transplantation. We review the challenges and pathology associated with 
HCV liver graft infection, highlight current and future strategies of DAA treatment timing, and 
discuss the potential role of entry inhibitors that might be employed synergistically with DAAs to 
inhibit graft infection.
Introduction
Hepatitis C virus (HCV) infection is the etiologic agent necessitating more than half of all 
liver transplantations (LTs) in North America and Europe15–19. The engrafted liver 
universally becomes infected and undergoes rapid progression to serious liver disease; HCV 
infection is thereby associated with the poorest post-transplantation survival rates compared 
to other etiologies leading to LT20. The even more accelerated natural history of allograft 
HCV in patients undergoing re-transplantation has made re-transplantation an ethically 
challenging proposition. Recently developed direct-acting antiviral (DAA) therapies have 
proven effective in treating chronic HCV infection, and appear more effective in the LT 
setting than conventional interferon (IFN)-based treatments in genotype 1 patients. However, 
treatment options are still limited for those needing LT consequent to HCV infection, as 
transplantation requires immunosuppressive reagents to avoid graft rejection with potential 
drug-drug interactions, the diminished health of this patient population, and the metabolic 
burden placed on the newly engrafted liver by co-administered pharmaceutical agents.
The most straightforward means of avoiding the pathogenesis of liver graft infection would 
be to instate preventative measures to avoid graft infection, but the strong efficacy of current 
DAAs may allow withholding antiviral treatment during operative stage and addressing 
HCV infection post-operatively. Here, we review the specific hurdles associated with HCV 
infection in LT, evidence supporting treatment strategies of patients needing transplantation, 
and the outlooks for prophylactic measures against liver graft infection.
Challenges of HCV liver graft infection
Universal graft infection in HCV RNA positive patients
Due to the current burden of HCV on transplants, the new potent DAAs are hoped to reduce 
transplantation activity, preemptively reducing the numbers of patients presenting with 
hepatocellular carcinoma (HCC) and decompensated cirrhosis21. To achieve this goal, 
however, comprehensive screening is necessary, since the majority of patients with chronic 
HCV infection only seek medical care following liver-related complications22. A positive 
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outlook is warranted given that a recent analysis indicates that a >90% decline in total 
infections by 2030 could be achievable, though this will require a 3 to 5-fold increase in 
diagnosis and treatment23. However, the public health strategy approaching this widespread 
problem must remain to hope for the best while planning for the worst.
HCV recurrence after LT remains universal in patients with detectable serum HCV RNA 
pre-transplantation. Even patients who are below detection levels for serum HCV RNA on 
therapy prior to transplantation have a 30% incidence of relapse, excluding those proven to 
have sustained virological response (SVR) to therapy for an extended period24. HCV 
recurrence is a critical medical problem and responsible for an increased risk of death and of 
graft failure. Positive detection of HCV RNA in recipients prior to transplantation associates 
with a diminished 5-year patient survival (69.9% vs. 76.6%, P<0.0001) and allograft 
survival (56.8% vs. 67.7%, P<0.0001)25; reinfection is a serious problem not only for the 
recipient, but also taxes the precious resource of suitable donated organs.
Rapid fibrosis progression after liver transplantation
The diminished 5-year survival rate is attributed to an accelerated development of pathology 
due to the immune-suppressive agents administered to prevent graft rejection. While the 
average time of progression from initial HCV infection to cirrhosis is about 30 years, 20–
30% of transplant recipients develop cirrhosis within 5 years26. While only 30% of non-
transplant cirrhotic patients have liver decompensation after 10 years of cirrhosis, more than 
40% of graft recipients decompensate within the 12 months following LT, of whom less than 
50% survive the following year. While the progression to fibrosis in the context of HCV 
recurrence varies widely depending on individual patient characteristics, the average time of 
progression to cirrhosis after LT is 10 to 12 years27. Re-transplantation is the only 
therapeutic option to achieve long-term survival of patients with decompensated cirrhosis 
after transplantation. Due to both poor patient and graft post-transplant survival rates, and 
the paucity of suitable organ donations, re-transplantation is not a sustainable option in most 
countries28.
A critical clinical challenge is to identify scenarios of early and rapid fibrosis development 
to employ early intervention while minimizing liver damage, highlighting the importance of 
diagnostic development. The previous consensus opinion was that IFN-based antiviral 
therapy should be initiated after detecting chronic hepatitis of the liver graft, usually >F1 on 
the METAVIR scoring system. The diagnosis of HCV recurrence is typically based on liver 
biopsy detection, since biopsies also can reveal severity of disease progression and exclude 
other possible diagnoses. It has been recently shown that significant periportal sinusoidal 
fibrosis in early biopsies (<6 months) is a good predictor of severe HCV recurrence29. The 
use of serum markers that decisively indicate fibrosis progression and other non-invasive 
techniques that measure liver stiffness will contribute to future decision-making in post-
transplantation HCV treatment. Liver stiffness values of <8.7 kPa have a 90% negative 
predictive value and can be utilized as a threshold in defining significant fibrosis30. Pressure 
levels exceeding 6 mmHg of hepatic venous pressure likewise indicate fibrosis31.
Robust recurrence of HCV RNA levels soon after transplantation is associated with poor 
prognosis, so early monitoring of HCV levels is critical. Robust recurrence occurs in 2 to 8% 
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of patients often resulting in fibrosing cholestatic hepatitis (FCH). FCH is characterized by 
high levels of cholestatic enzymes and the presence of extensive dense portal fibrosis with 
immature fibrous bands extending into the sinusoidal spaces, ductular proliferation, 
cholestasis, and moderate mononuclear inflammation detected in liver graft biopsies32. 
Without response to antiviral agents, FCH typically proceeds to complete liver failure.
Multiple risk factors contributing to rapid and severe fibrosis progression have been 
identified. High HCV RNA levels in either serum or liver associates with increased 
progression to cirrhosis, graft loss, and death33. Recipient and donor characteristics 
associated with poor outcome include female gender, donor age, and graft steatosis, while 
human leukocyte antigen (HLA) matching and IL28B genotype negatively associate with 
poor outcome18,34,35. While some of these factors can be selected for before transplantation, 
others are unpredictable and only antiviral treatment can improve the prognosis of transplant 
recipients.
The strategic options of HCV treatment with LT can be divided based on timing of 
treatment; HCV clearance pre-transplant, inhibition of graft infection concomitant with 
transplantation, or antiviral treatment after graft infection (Fig. 1).
DAA-based strategies for prevention and treatment of liver graft infection
HCV cure pre-transplant
The clearly optimal tact is to tackle reinfection early by eliminating HCV infection prior to 
transplantation. This strategy has been difficult to apply until recent DAA approval, since 
IFN-based therapies have limited efficacy for those with advanced disease while on a 
transplantation waitlist with SVR being achieved in only 8–39% of cases. The IFN 
tolerability is generally poor in these patients and contraindicated in patients with 
decompensated cirrhosis requiring either dose reduction (70%) or early discontinuation 
(30%) of treatment. The results of a phase 2 clinical study of administration of sofosbuvir 
with ribavirin (RBV) to 61 patients on waitlists for LT show that this tact with DAAs is 
effective6. Of the 43 patients who displayed viral response prior to transplantation, 70% 
maintained viral clearance 12 weeks post-transplantation. However, the efficacy of this 
strategy is genotype dependent and managing DAA combinations in the pre-transplant 
period is challenging. The use of sofosbuvir/RBV in advanced cirrhosis may contribute to 
lactic acidosis in approximately 14% of patients36. Charlton et al. investigated in the 
SOLAR-1 trial including the NS5A inhibitor ledipasvir in combination with sofosbuvir and 
RBV for individuals with cirrhosis and moderate or severe hepatic impairment due to 
genotype 1 and 4 infections37. SVR-12 was achieved in 86–89% in this difficult-to-treat 
cohort. The inclusion of ledipasvir or daclatasvir with sofosbuvir and RBV have been also 
investigated in the SOLAR-2 and ALLY-1 studies, respectively, focusing on patients with 
advanced liver disease pre-transplantation or with recurrent HCV post-transplantation38–40. 
In the SOLAR-2 study, patients with the sofosbuvir-sensitive HCV genotypes 1 or 4 were 
treated for 12 or 24 weeks with sofosbuvir, ledipasvir, and RBV. Preliminary results revealed 
high SVR rates of 85%–88%, irrespective of treatment duration in genotype 1. Longer 
treatment duration was superior (SVR rate of 86% vs. 57%) for patients with genotype 4 
infection and effective antiviral therapy was associated with improvement in liver histology, 
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MELD and Child-Pugh (CP) scores40. For some decompensated cirrhotic patients, however, 
MELD or CP scores increased. Searching for prognosis factors of clinical/biological 
response instead of only viral response is an ongoing and needed area of investigation.
The ALLY-1 phase-III study included 60 patients with advanced cirrhosis treated with 
daclatasvir, sofosbuvir and RBV39. While overall the SVR12 was 83%, response depended 
on severity of liver disease; 92%, 94% and 56% for CP A, B and C respectively. These 
findings suggest that further studies are required to define the best therapy management for 
CP C patients.
While the inclusion of sofosbuvir has had an impact on the management of genotype 1 
infection, the use of this drug has less significantly improved treatment for genotype 3 
infection. Foster et al. analyzed addition of NS5A inhibitors to sofosbuvir and RBV in 
patients with decompensated cirrhosis due to genotypes 1 or 340,41. The response rates 
varied from 44% to 88%, depending on genotype, NS5A inhibitor, and the use of RBV. 
Adding ledipasvir to sofosbuvir and RBV was inferior to daclatasvir plus sofosbuvir in 
patients with genotype 3 infection. Over 40% of patients experienced improvement in liver 
function with a mean improvement of >2 points of MELD score. Overall, these 
combinations showed excellent efficacy results and safety profiles, although some patients 
experienced worsening of their MELD scores. However the severity of cirrhosis remains an 
impediment to response, even with the new combinations of DAAs. Although the 
combination of sofosbuvir and NS5A inhibitor velpatasvir for 12 weeks provides SVR in 
over 95% of patients without cirrhosis42,43, SVR rate was 83% (n=90) in patients with 
decompensated cirrhosis44. However, the addition of ribavirin to this combination improves 
the SVR rate of 94%, even in cirrhotic patients (n=87)44.
The critical argument for treatment before transplantation is the prospect of avoiding LT 
altogether for individuals with liver disease that has not progressed to hepatocellular 
carcinoma. About 2/3 of patients achieve clinical and biological improvement during 
treatment in studies enrolling decompensated cirrhotic patients37,39,44,45. However, critical 
review reveals that 1/3 of patients do not improve or worsen during treatment, regardless of 
virological response. For those who do improve, the difference is often modest with 
variations of only 1 or 2 points in MELD score. In a recent meta-analysis involving five 
studies and including 533 patients, 28% experienced an improvement of MELD score over 
346. A number of patients do improve to the point where LT is avoidable. A French cohort 
study that included 183 patients awaiting transplantation showed that of 53 patients with 
decompensated cirrhosis, 36% had a complete clinical and biological response, meaning a 
CP A at the end of treatment45. The best improvement was in those with the least disease 
progression: those with baseline CP with an area under the curve (AUC) of 0.81, the CP 
threshold of improvement being 7.5. This raises further questions, since some patients keep 
improving over longer periods of follow-up. When considering longer times while being on 
waitlists for LT, comorbidities need to be considered. Optimum conditions and thresholds 
have not been defined for removing patients from waitlists. Although we could expect 
significant improvement for 1/3 of patients, this improvement is more likely for patients with 
less severe disease. For individuals with more severe disease, one needs to practice caution 
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since treating HCV in patients to only get partial biological improvement may be 
deleterious.
Waitlisted patients with HCC, who normally present with compensated cirrhosis, have 
several approved regimens available albeit with limited efficacy. In fact, treatment may be 
futile in about 30% of patients considering the rate of dropout before LT and early HCC 
recurrence after LT47. The severe disease state of those on the transplantation list can limit 
treatment options and the 12 weeks needed to confirm SVR status is not always afforded 
pre-transplantation. Patients with severe end-stage liver disease prior to LT or who require 
complicated post-operative treatment are frequently ineligible for pre-emptive interferon 
therapy.
DAA treatment after HCV graft infection
At present, two therapeutic approaches can be considered after transplantation: the pre-
emptive strategy involving treatment in the first month following transplantation, or to hold 
off treatment until chronic hepatitis is observed. Despite the clear benefits of early treatment, 
the pre-emptive strategy is historically not employed due to safety and efficacy limitations of 
initiating IFN-based antiviral therapy during the post-operative period48–52. New DAA IFN-
free combination therapy revives this strategy although due to the novelty of these therapies, 
the evidence regarding efficacy is lacking. Factors influencing the future employ of the pre-
emptive strategy will depend on safety, cost, and tolerability of next-generation DAAs 
relative to typical liver graft damage incurred before assessment of HCV recurrence.
On the other hand, treating HCV recurrence has been the standard therapy and until 2011 
involved 48 weeks of PEG-IFN and RBV treatment. Three systematic reviews have reported 
an SVR rate in these conditions of only approximately 30% with limitations of tolerability 
including bacterial infections, haematological toxicity, and graft rejection53–55. Early 
virological response (EVR) is a major predictive factor associated with SVR56,57. However, 
effective antiviral treatment post-transplantation has clear benefits in preventing disease 
progression58–63. First-generation protease inhibitors, telaprevir or boceprevir, were the 
initial agents tested in treating recurrent HCV post-transplantation. Their inclusion with 
PEG-IFN and RBV improved SVR rates by 50–65% in genotype 1 HCV-infected recipients 
however with a worse safety profile and potent drug-drug interactions64,65. Although 
feasible, these regimens required close monitoring and great expertise of caregivers leading 
to their retirement. The new generation of DAAs has further changed the treatment 
landscape in post-transplantation antiviral treatment, demonstrated in two studies where the 
initiation of treatment was a year after liver engraftment. Sofosbuvir plus RBV treatment has 
a 70% efficacy rate in yielding SVR, roughly equivalent to the virological response seen 
when clearing the virus pre-transplantation 6. Although this response efficacy is not optimal, 
it demonstrates efficacy and tolerability even in the most severe patients66. However, a more 
complex cocktail of DAAs can be more efficacious, and several studies describing this have 
already been communicated and/or published, summarized in Table 1. Data simultaneously 
comes from both open-label studies and real-life cohorts (HCV-TARGET and CUPILT 
studies). The SVR 12 rates are usually >90%, better than SVR12 rate treating 
decompensated cirrhotic prior to LT, and tolerance is excellent. In the SOLAR-1 study 
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assessing post-transplantation treatment, progressive liver disease was associated with 
lowered response, however all 6 individuals that had FCH achieved SVR 12 weeks after the 
end of treatment37. Although the treatment of HCV in transplant patients has been 
significantly improved and simplified, several issues remain to be clarified. This shows the 
promise of DAAs and combinatorial therapy; multiple targets and mechanisms of action 
synergize to eliminate the virus.
The optimal duration of therapy remains to be defined. While a number of risk factors of 
treatment failure were identified for IFN-based regimens, no risk factors have been identified 
for new DAAs except genotype 3. In the non-transplant setting, most studies comparing 
different treatment durations did not show any benefit of longer treatment and better 
adherence, fewer side effects, and lower cost associated with a shorter duration. In the 
transplant setting, robust data is currently lacking and many studies conservatively use 24-
weeks of treatment in this special population until more evidence is collected.
The use of RBV in future regimens is not yet established and could be abandoned once next-
generation DAAs with higher efficacy are added. There remains a significant benefit of RBV 
in patients with severe liver disease and recurrent HCV post-transplantation41,67,68.
In LT patients, renal impairment is common and should be properly evaluated before 
initiating antiviral therapy, especially sofosbuvir-based regimens69. The metabolism of 
sofosbuvir is renal and its use is not recommended in patients with creatinine clearance 
below 30 ml/min until an appropriate dosage is determined. A Phase IIb, open-label study of 
200 mg or 400 mg sofosbuvir and RBV for 24 weeks in HCV genotype 1 or 3 patients, and 
ledipasvir/sofosbuvir in individuals with genotype 1 and 4 infection with renal insufficiency 
is ongoing (Clinicaltrials.gov:NCT01958281). For other available DAAs, the metabolism is 
hepatic. Although no detrimental effect is expected in RBV-free combination, in a recent 
communication of the ANRS C023 CUPILT group, a slight but significant reduction in 
creatinine clearance during treatment was reported (from 72.7±29.0 to 66.3±25.7mL/min. 
between baseline and end of treatment; p<0.0001) using the combination of sofosbuvir and 
daclatasvir70. But it should better define which patients who worsen. In a recent multicentre 
trial of LT recipients with recurrent HCV infection treated with sofosbuvir based regimens, 
renal improvement was observed in the majority (58%) of patients 71. Those patients with 
SVR at 12 weeks post-treatment were more likely to have renal improvement, indicating that 
HCV affects renal health71.
Drug-drug interactions between DAAs and immunosuppressive drugs, mainly calcineurin 
inhibitors, remain a concern with these regimens. Simeprevir, a second generation protease 
inhibitor, is a partial cytochrome P450 (CYP) 3A inhibitor. Since the immunosuppressant 
cyclosporine is likewise a partial CYP3A inhibitor, combination results in accumulation of 
both drugs in the blood, and coadministration is discouraged72. Ombitasvir, paritaprevir, 
ritonavir, and dasabuvir require dosing modifications for calcineurin inhibitors tacrolimus 
and cyclosporine73,74. Conversely, sofosbuvir, ledipasvir and daclatasvir do not seem to 
interact with calcineurin inhibitors73. However, close monitoring before, during and after 
DAA therapy remains essential. In the ANRS C023 CUPILT study, 59% of 130 patients 
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treated with sofosbuvir and daclatasvir after LT had to change dosage of one 
immunosuppressive drug during therapy70.
Finally, the optimal timing for initiation of therapy post-transplantation remains to be 
determined. Antiviral therapy is usually initiated only when histologically proven recurrent 
HCV occurs (fibrosis stage ≥2 on the METAVIR score or severe and rapid progression of 
fibrosis as observed in cholestatic hepatitis). This decision was based on the tolerability of 
the classic IFN-based regimen, which required post-transplantation recovery time to regain 
health. Development of IFN-free therapy allows treatment of patients earlier after LT 
without waiting for disease markers indicating HCV recurrence. This strategy is reasonably 
based, but without scientific evidence of its efficacy. Nonetheless, earlier treatment appears 
safe and effective and the potential risk in allowing fibrosis progression on liver graft could 
raise ethical issues. Treating early after LT could help to overcome the issue of 
differentiating HCV recurrence and rejection and it could also prevent rejection episodes 
induced by viral clearance while immunosuppressive levels are still high at early stages after 
LT. It has been reported that immunosuppressive levels decrease significantly in patients 
responding to antiviral therapy as the viral clearance improves hepatic microsomal function 
and elevated regulatory T cell levels may decline75.
Perspective for prevention of graft infection concomitant with 
transplantation: HCV entry inhibitors
Viral entry has been demonstrated to play an essential role during re-infection of the graft 
after LT76,77. Thus, concomitant treatment of safe and effective entry inhibitors, including 
virus-targeting neutralizing antibodies (nAbs), during and immediately after transplantation 
may prove an effective means of preventing graft infection without allowing allograft 
damage78. This concept is supported by the experience in prevention of HBV graft infection 
where hepatitis B immune globulin in combination with nucleos(t)ide analogues can reduce 
HBV recurrence in LT patients to 4%77,79–81. Entry inhibitors have been shown to 
effectively inhibit HCV infection, work synergistically with DAAs, and have proven to be 
safe and effective in humanized mice82. While most of these agents are at a preclinical stage 
of development, the results of first clinical trials with anti-envelope antibodies14,83,84 and a 
small molecule host-targeting inhibitor85 suggest that they may be future tools in the 
antiviral arsenal during transplantation. Strategies for blocking viral entry during liver graft 
infection can either target the virus or host entry factors:
Anti-envelope antibodies
A high rate of viral diversity, glycosylation of the HCV glycoproteins, and association with 
apolipoproteins aids the escape of HCV from neutralizing antibodies (nAbs)86–91(reviewed 
in 89). In the course of HCV infection, nAbs develop that mostly target regions of E2 that 
interact with the host receptor CD8187,92–94. The crystal structure of the core of 
glycoprotein E295,96 defined the face of the protein where the majority of nAbs bind. 
Polyclonal and monoclonal nAbs taken from patients with chronic HCV infection or 
administered by gene therapeutic approaches are capable of inhibiting infection of human 
liver chimeric mice9,97–101. In patients, nAbs targeting the HCV envelope glycoprotein 
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(MBL-HCV1) effectively delayed viral rebound, proving the principle that immunotherapy 
will prove an effective addition to the synergistic antiviral arsenal14. Current studies are 
underway in combining MBL-HCV1 with DAAs to optimize therapeutic efficacy of this 
approach with the latest tools. Recent clinical trials of human HCV immune globulin 
(HCIG) in combination with DAAs show that administration of the immune globulin is safe 
and more effective than with DAAs alone84. However a potential challenge in utilizing nAbs 
for prevention of infection is identical to the problem during chronic infection, i.e. genetic 
adaptation enabling viral escape14. Complementing anti-envelope antibodies, small 
molecules have been identified to interfere with viral entry102–105.
Host-targeting entry inhibitors
One solution that could feasibly avoid the problem of viral escape from antiviral antibodies 
would be through targeting host entry factors (Fig. 2)78,106. Indeed, infection of HCV 
variants that escape host anti-envelope antibodies or exhibit resistance to DAAs are 
effectively blocked by host-targeting entry inhibitors76,82,107–109, Host-targeting agents have 
been investigated for multiple steps of viral entry. HCV virions circulate in dynamic 
complex with lipoproteins and apolipoproteins110,111. The earliest step of HCV attachment 
is mediated by apolipoprotein E binding to heparan sulfates on the baso-lateral surface of the 
hepatocyte112. Inhibitors of heparan sulfate attachment such as the green tea polyphenol 
epigallocatechin-3-gallate (EGCG) are generally safe and can impair infection in cell culture 
systems113,114, although in HCV mouse models the addition of EGCG adds no observable 
advantage over anti-envelope antibodies alone115. The next step of the HCV entry process is 
interaction of the virion with scavenger receptor B1 (SR-B1). Antibodies to SR-B1 
markedly inhibit HCV infection in small animal models11,13 and prevent antiviral resistance 
to DAAs116. Inhibition of the lipid transfer activity of SR-B1 is sufficient to inhibit 
infection117. A small chemical inhibitor of SR-B1, ITX5061, has been tested in patients 
undergoing transplantation with HCV infection85. Genotype 1 patients under treatment had 
sustained reduction of viral load, and the genetic variation of the quasispecies was limited85. 
After this initial attachment, a sequence of events takes place including the triggering of 
signaling pathways involving host kinases such as epidermal growth factor receptor (EGFR) 
to cluster essential entry factor claudin 1 (CLDN1) and CD81118,119. Erlotinib, a small 
molecule inhibitor of EGFR, has been shown to inhibit HCV infection in both cell culture 
and animal models118. Antibodies that recognize CD81 have also been shown in small 
animal models to inhibit HCV infection12,120. Anti-CLDN1-specific antibodies are not only 
effective in preventing HCV infection, but can prevent and cure HCV infection in 
humanized mice in monotherapy without resistance and observable side effects10,121,122. 
The anti-CLDN1 antibody has been shown to be highly synergistic with DAAs82, prevent 
antiviral resistance by impairing viral spread108. There are a number of other host entry 
factors such as occludin123,124, Niemann-Pick C1-like 1 (NPC1L1) 125, transferrin receptor 
1126, and serum response factor binding protein 1 (SRFBP1)127. A clinically approved small 
chemical inhibitor of NPC1L1 has likewise shown efficacy in small animal models and to 
synergize with DAA125,128. Future research will enable the discovery and development of 
host-targeting entry inhibitors of optimal safety in administration and efficiency in 
synergizing with DAAs to play a key role in increasing the cure rates in LT.
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Advantages and disadvantages
The success of next-generation DAAs in treatment raises the debate of whether HCV entry 
inhibitors have a place in future clinical practice128,129. There are a number of advantages 
and disadvantages to using entry inhibitors78,130. Strengths include their capacity to be used 
in targeting intervention around transplantation with a short duration of treatment. The 
barrier for resistance appears to be higher for host-targeting entry inhibitors than for DAA 
when used in monotherapy10,108. Given their complementary mechanism of action to 
DAAs106 and efficacy against DAA-resistant viruses108,131 entry inhibitors may offer a 
perspective for the patient population who fail preemptive therapy while preventing costly 
post-transplant therapy. The high level of synergy of entry inhibitors with DAAs observed in 
cell culture and animal models indicates that these agents could shorten treatment time and 
circumvent the development of antiviral-resistant variants10,82,116. Drawbacks include that a 
number of entry inhibitors are only now reaching clinical development stages. There are 
more DAAs in the drug development pipeline that may not be limited by the current safety 
issues of resistance and complications of renal failure. Targeting host factors will also 
require careful surveillance of side-effects106 and viral escape has been described14,131–134. 
Furthermore, the numbers of individuals with serious HCV-related liver disease will decline, 
as will prices for the DAA regimens.
Other approaches targeting host factors downstream of HCV cell entry106,135 include 
microRNA (miRNA) antagonists (antagomirs) or cyclophilin inhibitors 136,137. A key 
miRNA that boosts HCV replication, miR-122, acts by shifting HCV genome activity away 
from translation and toward replication138. Antisense agents targeting miR-122 have been 
shown to be safe and efficient in primate models and patients139–141. Cyclophilin, a host 
factor required for viral replication is efficiently inhibited by alisporivir, a host-targeting 
agent in clinical development 142. Whether these strategies are feasible in LT remains to be 
shown.
Summary and conclusion
Treatment of patients in need of LT as a result of HCV-associated advanced disease is a 
sensitive and complicated tree of decision-making. The successful use of DAAs as 
prophylactic and therapeutic agents against HCV infection, both before and following 
transplantation, promises to assist those likely increasing numbers of individuals who find 
themselves in this historically difficult-to-treat population. Randomized clinical trials are 
ongoing to define the role of entry inhibitors in prevention of graft infection.
Acknowledgments
The authors would like to thank Dr. Mirjam B. Zeisel and Dr. Che C. Colpitts (both Inserm U1110, University of 
Strasbourg, France) for critical reading of the manuscript. T.F.B acknowledges grant support by the European Union 
(ERC-2008-AdG-HEPCENT, ERC-AdG-2014-HEPCIR, FP7 HepaMab, and Interreg IV FEDER-Hepato-Regio-
Net 2012), the Agence Nationale de Recherche sur le SIDA (ANRS) and the Direction Générale de l’Offre de Soins 
(A12027MS). R.T.C. receives grant support from NIH DK078772. This work has been published under the 
framework of the LABEX ANR-10-LABX-0028_HEPSYS and benefits from a funding from the state managed by 
the French National Research Agency as part of the Investments for the future program.
Felmlee et al. Page 10
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and 
hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 
2013; 57(1):249–57. [PubMed: 22532055] 
2. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with 
chronic hepatitis C virus infection. Gastroenterology. 2011; 140(4):1182–8. e1. [PubMed: 
21184757] 
3. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost 
in the United States. Hepatology. 2013; 57(6):2164–70. [PubMed: 23280550] 
4. Curry MP, Smith HL, Chung RT, et al. Peri-transplant treatment with anti-HCV E2 human 
monoclonal antibody MBL-HCV1 in combintaion with a protease inhibitor results in undetectable 
HCV RNA in the early post-transplant period. Journal of Hepatology. 2014:S471.
5. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver 
transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013; 13(6):
1601–5. [PubMed: 23593993] 
6. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection 
after liver transplantation: an open-label study. Gastroenterology. 2015; 148(1):100–7. e1. [PubMed: 
25261839] 
7. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver 
transplantation. Liver Int. 2013; 33(Suppl 1):56–62. [PubMed: 23286847] 
8. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C 
after liver transplantation: a multicenter experience. J Hepatol. 2014; 60(1):78–86. [PubMed: 
23994384] 
9. Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus 
quasispecies challenge. Nat Med. 2008; 14(1):25–7. [PubMed: 18064037] 
10. Mailly L, Xiao F, Lupberger J, et al. Clearance of persistent hepatitis C virus infection in 
humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol. 2015; 33(5):
549–54. [PubMed: 25798937] 
11. Meuleman P, Catanese MT, Verhoye L, et al. A human monoclonal antibody targeting scavenger 
receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. 
Hepatology. 2012; 55(2):364–72. [PubMed: 21953761] 
12. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C 
virus infection in vivo. Hepatology. 2008; 48(6):1761–8. [PubMed: 19030166] 
13. Vercauteren K, Van Den Eede N, Mesalam AA, et al. Successful anti-scavenger receptor class B 
type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants 
with in vitro resistance to SR-BI-targeting agents. Hepatology. 2014; 60(5):1508–18. [PubMed: 
24797654] 
14. Chung RT, Gordon FD, Curry MP, et al. Human monoclonal antibody MBL-HCV1 delays HCV 
viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 
2013; 13(4):1047–54. [PubMed: 23356386] 
15. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 
2013 practice guideline by the American Association for the Study of Liver Diseases and the 
American Society of Transplantation. Hepatology. 2014; 59(3):1144–65. [PubMed: 24716201] 
16. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk 
factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J 
Transplant. 2010; 10(6):1420–7. [PubMed: 20486907] 
17. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in 
recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 
2004; 10(9):1120–30. [PubMed: 15350002] 
18. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 
14(Suppl 2):S36–44. [PubMed: 18825724] 
19. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002; 36(5 Suppl 1):S30–4. 
[PubMed: 12407574] 
Felmlee et al. Page 11
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
20. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in 
Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57(3):
675–88. [PubMed: 22609307] 
21. Deuffic-Burban S, Mathurin P, Rosa I, et al. Impact of emerging hepatitis C virus treatments on 
future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014; 46(2):
157–63. [PubMed: 24119483] 
22. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of 
hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National 
Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012; 55(6):1652–61. 
[PubMed: 22213025] 
23. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease 
burden. J Viral Hepat. 2014; 21(Suppl 1):60–89. [PubMed: 24713006] 
24. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated 
cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39(3):
389–96. [PubMed: 12927925] 
25. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C 
infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122(4):889–
96. [PubMed: 11910340] 
26. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C 
virus-related graft cirrhosis after liver transplantation. Hepatology. 2000; 32(4 Pt 1):852–8. 
[PubMed: 11003634] 
27. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus 
genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 
1999; 29(1):250–6. [PubMed: 9862874] 
28. Carrion JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver 
transplantation. J Hepatol. 2010; 53(5):962–70. [PubMed: 20800307] 
29. Marino Z, Mensa L, Crespo G, et al. Early periportal sinusoidal fibrosis is an accurate marker of 
accelerated HCV recurrence after liver transplantation. J Hepatol. 2014; 61(2):270–7. [PubMed: 
24703854] 
30. Carrion JA, Torres F, Crespo G, et al. Liver stiffness identifies two different patterns of fibrosis 
progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology. 
2010; 51(1):23–34. [PubMed: 19839063] 
31. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of 
severe hepatitis C recurrence after liver transplantation. Hepatology. 2006; 43(3):492–9. [PubMed: 
16496308] 
32. Berenguer M, McCaughan G. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to 
agree on diagnostic criteria. Liver Transpl. 2013; 19(2):115–7. [PubMed: 23197377] 
33. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver 
transplantation for hepatitis C. Hepatology. 1998; 28(3):823–30. [PubMed: 9731579] 
34. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors 
correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. 
Gastroenterology. 2010; 139(5):1577–85. 85 e1–3. [PubMed: 20708617] 
35. Veldt BJ, Duarte-Rojo A, Thompson AJ, et al. Recipient IL28B polymorphism is an important 
independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic 
hepatitis C. Am J Transplant. 2012; 12(3):737–44. [PubMed: 22300408] 
36. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus related 
cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2015; doi: 10.1016/j.jhep.
2015.11.034
37. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment 
of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015; 149(3):649–
59. [PubMed: 25985734] 
38. Manns M, Forns X, Samuel D, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in 
decompensated and post liver transplantation patients with HCV infection: preliminary results of 
the prospective SOLAR 2 trial. J Hepatol. 2015; 62(S2):S187.
Felmlee et al. Page 12
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
39. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir With Sofosbuvir and Ribavirin for HCV 
Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016; doi: 
10.1002/hep.28446
40. Gambato M, Villanueva A, Abraldes JG, Altamirano J, Forns X. Clinical Trial Watch: Reports 
from the EASL International Liver Congress (ILC), Vienna, April 2015. J Hepatol. 2015; 63(3):
753–62. [PubMed: 26095181] 
41. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients 
with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is 
effective in HCV genotypes 1 and 3. J Hepatol. 2015; 62(S2):S190–S1.
42. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 
Infection. N Engl J Med. 2015; 373(27):2608–17. [PubMed: 26575258] 
43. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, 
and 6 Infection. N Engl J Med. 2015; 373(27):2599–607. [PubMed: 26571066] 
44. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with 
Decompensated Cirrhosis. N Engl J Med. 2015; 373(27):2618–28. [PubMed: 26569658] 
45. Coilly A, Pageaux G, Houssel-Debry P, et al. Improving liver function and delisting of patients 
awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? Hepatology. 2015; 
62(S1):257A.
46. Munoz SJ, Reich DJ, Rothstein KD, et al. Curing decompensated wait listed HCV patients with the 
new DAAs: the potential significant impact on liver transplant wait list and organ allocation. 
Hepatology. 2015; 62(S1):311A.
47. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or 
without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012; 
56(1):149–56. [PubMed: 22271250] 
48. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of 
peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for 
hepatitis C virus. Liver Transpl. 2011; 17(5):528–38. [PubMed: 21506241] 
49. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver 
transplantation: two randomized, controlled trials. Hepatology. 2005; 41(2):289–98. [PubMed: 
15660392] 
50. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver 
transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001; 33(1–2):1355–
7. [PubMed: 11267325] 
51. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive 
antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 
2005; 5(1):118–24. [PubMed: 15636619] 
52. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-
donor liver transplantation. Transplantation. 2004; 78(9):1308–11. [PubMed: 15548968] 
53. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with 
pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49(2):274–87. [PubMed: 
18571272] 
54. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral 
therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J 
Transplant. 2006; 6(7):1586–99. [PubMed: 16827859] 
55. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant 
candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective 
controlled studies. J Viral Hepat. 2008; 15(10):699–709. [PubMed: 18673428] 
56. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks 
associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver 
Transpl. 2006; 12(7):1067–76. [PubMed: 16622844] 
57. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: 
response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. 
Liver Transpl. 2008; 14(12):1766–77. [PubMed: 19025933] 
Felmlee et al. Page 13
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
58. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and 
ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004; 10(2):199–
207. [PubMed: 14762857] 
59. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of 
intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin 
combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003; 
52(2):283–7. [PubMed: 12524414] 
60. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin 
in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002; 8(11):
1000–6. [PubMed: 12424712] 
61. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces 
mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46(3):459–65. [PubMed: 
17196700] 
62. Walter T, Scoazec JY, Guillaud O, et al. Long-term antiviral therapy for recurrent hepatitis C after 
liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver 
Transpl. 2009; 15(1):54–63. [PubMed: 19109834] 
63. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C 
recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 
132(5):1746–56. [PubMed: 17484872] 
64. Coilly A, Dumortier J, Botta-Fridlund D, et al. Multicenter Experience with Boceprevir or 
Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes 
Past, What Lessons for Future? PLoS One. 2015; 10(9):e0138091. [PubMed: 26394142] 
65. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated 
recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148(1):
108–17. [PubMed: 25304641] 
66. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with 
severe recurrent hepatitis C after liver transplantation. Hepatology. 2015; 61(5):1485–94. 
[PubMed: 25557906] 
67. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, 
and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 
313(12):1223–31. [PubMed: 25706092] 
68. Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 
hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. 
Hepatology. 2015; 62(1):79–86. [PubMed: 25846144] 
69. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N 
Engl J Med. 2003; 349(10):931–40. [PubMed: 12954741] 
70. Coilly A, Fougerou C, De Ledinghen V, et al. The association of sofosbuvir and daclatasvir for 
treating severe recurrence of HCV infection after liver translplantation; results from a large French 
prospective multicentric ANRS CO23 CUPILT cohort. J Hepatol. 2015; 62(S2):S235.
71. Faisal N, Renner EL, Bilodeau M, et al. Impact of sofosbuvir-based regimens on renal function in 
liver transplant recipients: results of a multicenter study. Hepatology. 2015; 62(S1):312A. 
[PubMed: 25904459] 
72. Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug-Drug 
Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2015
73. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug 
interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug 
options in end-stage renal disease. Curr Opin Organ Transplant. 2015; 20(3):235–41. [PubMed: 
25944238] 
74. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver 
transplantation. N Engl J Med. 2014; 371(25):2375–82. [PubMed: 25386767] 
75. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, 
and risk for acute cellular rejection. Liver Transpl. 2003; 9(11):1159–65. [PubMed: 14586876] 
Felmlee et al. Page 14
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
76. Fafi-Kremer S, Fofana I, Soulier E, et al. Viral entry and escape from antibody-mediated 
neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med. 2010; 
207(9):2019–31. [PubMed: 20713596] 
77. Fofana I, Fafi-Kremer S, Carolla P, et al. Mutations that alter use of hepatitis C virus cell entry 
factors mediate escape from neutralizing antibodies. Gastroenterology. 2012; 143(1):223–33. e9. 
[PubMed: 22503792] 
78. Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. 
Antiviral Res. 2014; 104:136–42. [PubMed: 24525381] 
79. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to 
prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007; 132(3):931–
7. [PubMed: 17383422] 
80. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 
2012; 142(6):1373–83. e1. [PubMed: 22537446] 
81. Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B 
Recurrence. Int J Mol Sci. 2015; 16(8):17494–513. [PubMed: 26263973] 
82. Xiao F, Fofana I, Thumann C, et al. Synergy of entry inhibitors with direct-acting antivirals 
uncovers novel combinations for prevention and treatment of hepatitis C. Gut. 2015; 64(3):483–94. 
[PubMed: 24848265] 
83. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and 
pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. 
Liver Transpl. 2005; 11(8):941–9. [PubMed: 16035063] 
84. Terrault N, Satapathy SK, Therapondos G, et al. Prevention of Hepatitis C Virus (HCV) 
Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant 
(Pre-LT) Antiviral Therapy (AVT). Hepatology. 2014; 60(S1):206A.
85. Rowe IA, Tully DC, Armstrong MJ, et al. Effect of scavenger receptor BI antagonist ITX5061 in 
patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl. 2015
86. Helle F, Vieyres G, Elkrief L, et al. Role of N-linked glycans in the functions of hepatitis C virus 
envelope proteins incorporated into infectious virions. J Virol. 2010; 84(22):11905–15. [PubMed: 
20844034] 
87. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing 
antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 2007; 132(2):
667–78. [PubMed: 17258731] 
88. Zhang P, Zhong L, Struble EB, et al. Depletion of interfering antibodies in chronic hepatitis C 
patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl 
Acad Sci U S A. 2009; 106(18):7537–41. [PubMed: 19380744] 
89. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: A distant 
peak still worth climbing. J Hepatol. 2014; 61(1S):S34–S44. [PubMed: 25443345] 
90. Fauvelle C, Felmlee DJ, Crouchet E, et al. Apolipoprotein E Mediates Evasion From Hepatitis C 
Virus Neutralizing Antibodies. Gastroenterology. 2016; 150(1):206–17. e4. [PubMed: 26404951] 
91. Bankwitz D, Steinmann E, Bitzegeio J, et al. Hepatitis C virus hypervariable region 1 modulates 
receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing 
epitopes. J Virol. 2010; 84(11):5751–63. [PubMed: 20357091] 
92. Owsianka AM, Tarr AW, Keck ZY, et al. Broadly neutralizing human monoclonal antibodies to the 
hepatitis C virus E2 glycoprotein. J Gen Virol. 2008; 89(Pt 3):653–9. [PubMed: 18272755] 
93. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA. CD81 is required for 
hepatitis C virus glycoprotein-mediated viral infection. J Virol. 2004; 78(3):1448–55. [PubMed: 
14722300] 
94. Haberstroh A, Schnober EK, Zeisel MB, et al. Neutralizing host responses in hepatitis C virus 
infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 2008; 
135(5):1719–28. e1. [PubMed: 18718838] 
95. Kong L, Giang E, Nieusma T, et al. Hepatitis C virus E2 envelope glycoprotein core structure. 
Science. 2013; 342(6162):1090–4. [PubMed: 24288331] 
96. Khan AG, Whidby J, Miller MT, et al. Structure of the core ectodomain of the hepatitis C virus 
envelope glycoprotein 2. Nature. 2014; 509(7500):381–4. [PubMed: 24553139] 
Felmlee et al. Page 15
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
97. Vanwolleghem T, Bukh J, Meuleman P, et al. Polyclonal immunoglobulins from a chronic hepatitis 
C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C 
virus strain. Hepatology. 2008; 47(6):1846–55. [PubMed: 18452146] 
98. Akazawa D, Moriyama M, Yokokawa H, et al. Neutralizing antibodies induced by cell culture-
derived hepatitis C virus protect against infection in mice. Gastroenterology. 2013; 145(2):447–55. 
e1–4. [PubMed: 23673355] 
99. Meuleman P, Bukh J, Verhoye L, et al. In vivo evaluation of the cross-genotype neutralizing 
activity of polyclonal antibodies against hepatitis C virus. Hepatology. 2011; 53(3):755–62. 
[PubMed: 21319203] 
100. de Jong YP, Dorner M, Mommersteeg MC, et al. Broadly neutralizing antibodies abrogate 
established hepatitis C virus infection. Sci Transl Med. 2014; 6(254):254ra129.
101. Desombere I, Fafi-Kremer S, Van Houtte F, et al. Monoclonal anti-envelope antibody AP33 
protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology. 2015; 
doi: 10.1002/hep.28428
102. Perin PM, Haid S, Brown RJ, et al. Flunarizine prevents hepatitis C virus membrane fusion in a 
genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology. 
2015; doi: 10.1002/hep.28111
103. St Vincent MR, Colpitts CC, Ustinov AV, et al. Rigid amphipathic fusion inhibitors, small 
molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A. 2010; 
107(40):17339–44. [PubMed: 20823220] 
104. Lin LT, Chung CY, Hsu WC, et al. Saikosaponin b2 is a naturally occurring terpenoid that 
efficiently inhibits hepatitis C virus entry. J Hepatol. 2015; 62(3):541–8. [PubMed: 25450204] 
105. He S, Lin B, Chu V, et al. Repurposing of the antihistamine chlorcyclizine and related compounds 
for treatment of hepatitis C virus infection. Sci Transl Med. 2015; 7(282):282ra49.
106. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and 
treatment of chronic hepatitis C - perspectives and challenges. J Hepatol. 2013; 58(2):375–84. 
[PubMed: 23041307] 
107. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C 
virus infection of primary human hepatocytes. Gastroenterology. 2010; 139(3):953–64. 64 e1–4. 
[PubMed: 20685314] 
108. Xiao F, Fofana I, Heydmann L, et al. Hepatitis C virus cell-cell transmission and resistance to 
direct-acting antiviral agents. PLoS Pathog. 2014; 10(5):e1004128. [PubMed: 24830295] 
109. Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol. 2013; 
369:87–112. [PubMed: 23463198] 
110. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density 
hepatitis C virus RNA-containing particles. J Virol. 2002; 76(14):6919–28. [PubMed: 12072493] 
111. Felmlee DJ, Sheridan DA, Bridge SH, et al. Intravascular transfer contributes to postprandial 
increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology. 2010; 
139(5):1774–83. 83 e1–6. [PubMed: 20682323] 
112. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by 
apolipoprotein E binding to cell surface heparan sulfate. J Virol. 2012; 86(13):7256–67. 
[PubMed: 22532692] 
113. Ciesek S, von Hahn T, Colpitts CC, et al. The green tea polyphenol, epigallocatechin-3-gallate, 
inhibits hepatitis C virus entry. Hepatology. 2011; 54(6):1947–55. [PubMed: 21837753] 
114. Colpitts CC, Schang LM. A small molecule inhibits virion attachment to heparan sulfate- or sialic 
acid-containing glycans. J Virol. 2014; 88(14):7806–17. [PubMed: 24789779] 
115. O’Shea D, Law J, Egli A, et al. Prevention of HCV infection using a broad cross-neutralizing 
monoclonal antibody (AR4A) and Epigallocatechin-Gallate. Liver Transpl. 2015; doi: 10.1002/lt.
24344
116. Vercauteren K, Brown RJ, Mesalam AA, et al. Targeting a host-cell entry factor barricades 
antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut. 2015; 
doi: 10.1136/gutjnl-2014-309045
Felmlee et al. Page 16
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
117. Zahid MN, Turek M, Xiao F, et al. The postbinding activity of scavenger receptor class B type I 
mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology. 2013; 
57(2):492–504. [PubMed: 23081796] 
118. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus 
entry and possible targets for antiviral therapy. Nat Med. 2011; 17(5):589–95. [PubMed: 
21516087] 
119. Zona L, Lupberger J, Sidahmed-Adrar N, et al. HRas signal transduction promotes hepatitis C 
virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host 
Microbe. 2013; 13(3):302–13. [PubMed: 23498955] 
120. Ji C, Liu Y, Pamulapati C, et al. Prevention of hepatitis C virus infection and spread in human 
liver chimeric mice by an anti-CD81 monoclonal antibody. Hepatology. 2014; 61(4):1136–44. 
[PubMed: 25417967] 
121. Yamashita M, Iida M, Tada M, et al. Discovery of Anti-Claudin-1 Antibodies as Candidate 
Therapeutics against Hepatitis C Virus. J Pharmacol Exp Ther. 2015; 353(1):112–8. [PubMed: 
25628391] 
122. Fukasawa M, Nagase S, Shirasago Y, et al. Monoclonal antibodies against extracellular domains 
of claudin-1 block hepatitis C virus infection in a mouse model. J Virol. 2015; 89(9):4866–79. 
[PubMed: 25673725] 
123. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor 
required for infection of mouse cells. Nature. 2009; 457(7231):882–6. [PubMed: 19182773] 
124. Benedicto I, Molina-Jimenez F, Bartosch B, et al. The tight junction-associated protein occludin is 
required for a postbinding step in hepatitis C virus entry and infection. J Virol. 2009; 83(16):
8012–20. [PubMed: 19515778] 
125. Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol 
absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012; 18(2):281–5. 
[PubMed: 22231557] 
126. Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry 
factor. Proc Natl Acad Sci U S A. 2013; 110(26):10777–82. [PubMed: 23754414] 
127. Gerold G, Meissner F, Bruening J, et al. Quantitative Proteomics Identifies Serum Response 
Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Rep. 2015; 12(5):
864–78. [PubMed: 26212323] 
128. Uprichard SL, Sainz B Jr. Inhibition of hepatitis C entry: too soon to dismiss while many are still 
being denied treatment. Gut. 2015; 64(4):690–1. [PubMed: 25287483] 
129. Pawlotsky JM. Viral entry inhibition: too late for hepatitis C, but promising for other viral 
infections. Gut. 2015; 64(3):362–4. [PubMed: 25098973] 
130. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: 
towards the identification of new treatment targets. Gut. 2012; 61(Suppl 1):i25–35. [PubMed: 
22504917] 
131. Zhu H, Wong-Staal F, Lee H, et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: 
resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect 
Dis. 2012; 205(4):656–62. [PubMed: 22279172] 
132. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. Isolate-dependent use of 
claudins for cell entry by hepatitis C virus. Hepatology. 2014; 59(1):24–34. [PubMed: 23775920] 
133. Hopcraft SE, Evans MJ. Selection of a hepatitis C virus with altered entry factor requirements 
reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology. 2015; 62(4):
1059–69. [PubMed: 25820616] 
134. Colpitts CC, Zeisel MB, Baumert TF. When one receptor closes, another opens: Claudins and the 
hepatitis C virus E1 glycoprotein. Hepatology. 2015; 62(4):991–3. [PubMed: 25930717] 
135. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov. 
2013; 12(8):595–610. [PubMed: 23807378] 
136. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in 
liver disease. J Hepatol. 2015; 62(2):448–57. [PubMed: 25308172] 
137. Lin K, Gallay P. Curing a viral infection by targeting the host: the example of cyclophilin 
inhibitors. Antiviral Res. 2013; 99(1):68–77. [PubMed: 23578729] 
Felmlee et al. Page 17
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
138. Masaki T, Arend KC, Li Y, et al. miR-122 stimulates hepatitis C virus RNA synthesis by altering 
the balance of viral RNAs engaged in replication versus translation. Cell Host Microbe. 2015; 
17(2):217–28. [PubMed: 25662750] 
139. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in 
primates with chronic hepatitis C virus infection. Science. 2010; 327(5962):198–201. [PubMed: 
19965718] 
140. Van Der Ree M, de Vree ML, Stelma F, et al. A single subcutaneous dose of 2 mg/kg or 4 mg/kg 
of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, 
results in significatnt viral load reductions in chronic hepatitis c patients. J Hepatol. 2015; 
62(S2):S261.
141. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. 
N Engl J Med. 2013; 368(18):1685–94. [PubMed: 23534542] 
142. Guedj J, Yu J, Levi M, et al. Modeling viral kinetics and treatment outcome during alisporivir 
interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology. 2014; 59(5):
1706–14. [PubMed: 24375768] 
143. Pungpapong S, Werner KT, Aqel B, et al. Multicenter Experience using Sofosbuvir and 
Simeprevir with/without Rivavirin to Treat HCV Genotype 1 after Liver Transplantation. 
Hepatology. 2014; 60(S1):201A.
144. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of Simeprevir Plus Sofosbuvir, 
With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
Gastroenterology. 2016; 150(2):419–29. [PubMed: 26497081] 
145. Rowe IAM, Parker R, Guo K, Barton D, McKelvy J, Wong-Staal F, Adams D, McKeating J, 
Mutimer D. Effect of scavenger receptor B-I antagonist, ITX5061, on early hepatitis C virus 
kinetics in liver transplantation; results of a phase 1b clinical trial. Lancet. 2014 Feb.:S90.
Felmlee et al. Page 18
Lancet Infect Dis. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Timing of Antiviral Strategies for Successful Liver Transplantation in HCV-infected 
Patients
After a patient presents with a cirrhotic liver (upper left) with HCV infection (green dots) 
there are multiple strategies that have been proposed for having a successful, non-infected 
transplantation. Successful treatment eliminating the virus before transplantation (lower left) 
has proven successful to approximately 70% with DAAs35. Multiple lines of evidence show 
that immunoprevention and HCV entry antagonists can play a syngergistic role in blocking 
infection concomitant to transplantation (center, top). Permitting infection and treating later 
with DAAs (right top and bottom) has proven 70–97% successful depending on the study 
and drug employed53,54.
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Figure 2. Examples of HCV entry factors as targets to prevent graft infection with completed in 
vivo proof-of-concept
Several points of HCV entry are effective targets to prevent initial or ongoing liver graft 
infection. The HCV glycoprotein E1/E2 is critical for HCV entry (marker 1), and nAbs 
binding to E1/E2 have proven effective in animal models and clinically9,97,100. Early steps 
of HCV entry likely involve initial attachment of apoE to HSPG and utilization of SR-B1 
(marker 2). SR-B1 inhibitors have been effective in animal models and in the clinic in the 
context of liver transplantation11,13,85,145. HCV E2 directly binds to host entry factor CD81 
(marker 3), and antibodies binding CD81 prevent HCV infection in animal models12,120. 
Antibodies recognizing CLDN1 (marker 4) have proven effective in curing animal models of 
HCV infection10,121,122. Furthermore, small molecules erlotinib targeting EGFR118, a kinase 
promoting CD81-claudin-1 coreceptor formation, and ezetimibe targeting cholesterol 
transporter NP1CL1 (not shown) have been shown to inhibit HCV infection in humanized 
mouse models 125. Downstream of entry, microRNA 122 (miRNA) antagonists (antagomirs, 
marker 5) have been shown to effective and safe in animals and patients139,141. DAAs 
targeting virally encoded enzymes have revolutionized HCV treatment (marker 6).
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